Please login to the form below

Not currently logged in
Email:
Password:

Alecensa

This page shows the latest Alecensa news and features for those working in and with pharma, biotech and healthcare.

MSD launches EU’s first biosimilar Herceptin in UK

MSD launches EU’s first biosimilar Herceptin in UK

has insisted it can ride out the storm with new products such as multiple sclerosis therapy Ocrevus (ocrelizumab) and cancer drugs Perjeta (pertuzumab), Tecentriq (atezolizumab) and Alecensa (alectinib).

Latest news

  • Pfizer files third-gen ALK inhibitor for lung cancer Pfizer files third-gen ALK inhibitor for lung cancer

    of competitive pressure from Roche’s fast-growing rival Alecensa (alectinib), a second-generation inhibitor that is well-tolerated and has the added benefit of penetrating the brain, which can help ... Alecensa saw sales double to reach around $385m in

  • Roche faces biosimilar blitz in 2018 Roche faces biosimilar blitz in 2018

    Last year, Ocrevus, Tecentriq, Perjeta and Alecensa sales drove a 5% growth for Roche, along with label extensions for existing products and approvals for new medicines Ocrevus and Hemlibra in the ... US. Schwan added: “I am particularly pleased with

  • Roche gets FDA OKs for Alecensa and Zelboraf Roche gets FDA OKs for Alecensa and Zelboraf

    Roche gets FDA OKs for Alecensa and Zelboraf. Gains US licences for first-line use in lung cancer and a rare blood cancer. ... Approval of Alecensa for front-line use in Europe is expected in the next few weeks after it was recommended by the Committee

  • Roche wins CHMP nod for Alecensa licence extensions Roche wins CHMP nod for Alecensa licence extensions

    Roche wins CHMP nod for Alecensa licence extensions. Lung cancer monotherapy set for a broader European label. ... European regulatory advisors have given their backing to new uses of Roche’s lung cancer drug Alecensa (alectinib).

  • Amgen's Mvasi is first FDA-approved cancer biosimilar Amgen's Mvasi is first FDA-approved cancer biosimilar

    Roche is also in the midst of a fertile launch period for new medicines, with a clutch of new drugs - including Cotellic (cobimetinib) for melanoma, Alecensa (alectinib) for lung cancer, leukaemia

More from news
Approximately 14 fully matching, plus 15 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics